Cleerly02.11.22
Cleerly has added three new members to its Board of Directors.
The company recruited Kevin M. King, Glenn D. Steele Jr., M.D., Ph.D., and Roy Beveridge, M.D., to help guide the firm as it works to develop and commercialize its digital care pathway solution.
"We welcome Roy, Kevin, and Glenn to our Board of Directors. All three join our board with highly impressive backgrounds as leaders in the healthcare space," said James K. Min, M.D. FACC, founder and CEO of Cleerly. "Having the right experts on our team is key for us to accomplish our goals, and our new board members impeccably fit the bill."
King has nearly three decades of experience serving in leadership roles within medical device, digital healthcare services, and information technologies segments. He worked at iRhythm Technologies for a decade, leading the organization as president and CEO and remains a director of the company. He has also previously served as president, CEO and director at Affymetrix Inc., president and CEO of Thomson Healthcare, and a senior executive at GE Healthcare.
Steele serves as chairman of both GSteele Health Solutions, an independently operated venture helping healthcare organizations create value and improve quality, and City of Hope, an organization advancing cancer research and treatment protocols. He is the former chairman of xG Health Solutions and former president and CEO of Geisinger Health System.
Beveridge is currently a senior advisor at Avalere, and recently served as Humana’s chief medical officer, where he led clinical policy, population health and clinical quality initiatives. Beveridge has held similar roles for U.S. Oncology and McKesson specialty. A medical oncologist for more than 25 years, Beveridge’s recent work has focused on social determinants of health and improving the health of underserved populations.
Additionally, Cleerly has assembled a panel of board observers including Greg Banker, vice president of Vensana Capital; Cynthia Yee, principal at Vensana Capital; David Kim, M.D., managing director of DigiTX Partners; A.J. Shimoga, senior associate at Cigna Ventures; and Craig Cimini, managing director of Cigna Ventures.
Through value-based precision diagnostic solutions driven by machine intelligence, Cleerly enables comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging.
The company recruited Kevin M. King, Glenn D. Steele Jr., M.D., Ph.D., and Roy Beveridge, M.D., to help guide the firm as it works to develop and commercialize its digital care pathway solution.
"We welcome Roy, Kevin, and Glenn to our Board of Directors. All three join our board with highly impressive backgrounds as leaders in the healthcare space," said James K. Min, M.D. FACC, founder and CEO of Cleerly. "Having the right experts on our team is key for us to accomplish our goals, and our new board members impeccably fit the bill."
King has nearly three decades of experience serving in leadership roles within medical device, digital healthcare services, and information technologies segments. He worked at iRhythm Technologies for a decade, leading the organization as president and CEO and remains a director of the company. He has also previously served as president, CEO and director at Affymetrix Inc., president and CEO of Thomson Healthcare, and a senior executive at GE Healthcare.
Steele serves as chairman of both GSteele Health Solutions, an independently operated venture helping healthcare organizations create value and improve quality, and City of Hope, an organization advancing cancer research and treatment protocols. He is the former chairman of xG Health Solutions and former president and CEO of Geisinger Health System.
Beveridge is currently a senior advisor at Avalere, and recently served as Humana’s chief medical officer, where he led clinical policy, population health and clinical quality initiatives. Beveridge has held similar roles for U.S. Oncology and McKesson specialty. A medical oncologist for more than 25 years, Beveridge’s recent work has focused on social determinants of health and improving the health of underserved populations.
Additionally, Cleerly has assembled a panel of board observers including Greg Banker, vice president of Vensana Capital; Cynthia Yee, principal at Vensana Capital; David Kim, M.D., managing director of DigiTX Partners; A.J. Shimoga, senior associate at Cigna Ventures; and Craig Cimini, managing director of Cigna Ventures.
Through value-based precision diagnostic solutions driven by machine intelligence, Cleerly enables comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging.